References
- Varga J, Trojanowska M, Kuwana M. Pathogenesis of systemic sclerosis: recent insights of molecular and cellular mechanisms and therapeutic opportunities. J scleroderma relat disord. 2017;2(3):137–152.
- LeRoy EC, Black C, Fleischmajer R, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol. 1988;15(2):202–205.
- Murray PJ, Wynn TA. Protective and pathogenic functions of macrophage subsets. Nat Rev Immunol. 2011;11(11):723–737.
- Matsushita T, Takehara K. An update on biomarker discovery and use in systemic sclerosis. Expert Rev Mol Diagn. 2017;17(9):823–833.
- Kristiansen M, Graversen JH, Jacobsen C, et al. Identification of the haemoglobin scavenger receptor. Nature. 2001;409(6817):198–201.
- Frings W, Dreier J, Sorg C. Only the soluble form of the scavenger receptor CD163 acts inhibitory on phorbol ester-activated T-lymphocytes, whereas membrane-bound protein has no effect. FEBS Lett. 2002;526(1–3):93–96.
- Higashi-Kuwata N, Jinnin M, Makino T, et al. Characterization of monocyte/macrophage subsets in the skin and peripheral blood derived from patients with systemic sclerosis. Arthritis Res Ther. 2010;12(4):R128.
- Mathai SK, Gulati M, Peng X, et al. Circulating monocytes from systemic sclerosis patients with interstitial lung disease show an enhanced profibrotic phenotype. Lab Invest. 2010;90(6):812–823.
- Christmann RB, Sampaio-Barros P, Stifano G, et al. Association of interferon- and transforming growth factor beta-regulated genes and macrophage activation with systemic sclerosis-related progressive lung fibrosis. Arthritis Rheumatol. 2014;66(3):714–725.
- Nakayama W, Jinnin M, Makino K, et al. Serum levels of soluble CD163 in patients with systemic sclerosis. Rheumatol Int. 2012;32(2):403–407.
- Hassan WA, Baraka EA, Elnady BM, et al. Serum soluble CD163 and its association with various disease parameters in patients with systemic sclerosis. Eur J Rheumatol. 2016;3(3):95–100.
- Shimizu K, Ogawa F, Yoshizaki A, et al. Increased serum levels of soluble CD163 in patients with scleroderma. Clin Rheumatol. 2012;31(7):1059–1064.
- Bielecki M, Kowal K, Lapinska A, et al. Increased release of soluble CD163 by the peripheral blood mononuclear cells is associated with worse prognosis in patients with systemic sclerosis. Adv Med Sci. 2013;58(1):126–133.
- Kowal-Bielecka O, Bielecki M, Guiducci S, et al. High serum sCD163/sTWEAK ratio is associated with lower risk of digital ulcers but more severe skin disease in patients with systemic sclerosis. Arthritis Res Ther. 2013;15(3):R69.
- Frantz C, Pezet S, Avouac J, et al. Soluble CD163 as a potential biomarker in systemic sclerosis. Dis Markers. 2018;2018:8509583.